Minimising treatment-associated risks in systemic cancer therapy

Pharmacy World and Science

Volumn 30, Issue 2, 2008, Pages 161-168

  Jaehde, Ulrich ^a   Liekweg, Andrea ^a   Simons, Sven ^a   Westfeld, Martina ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cancer; Chemotherapy; Drug related problems; Medication errors; Oncology; Pharmaceutical care

Indexed keywords

ADVERSE DRUG REACTION; CANCER PATIENT; CANCER THERAPY; COCHRANE LIBRARY; DRUG INDUCED DISEASE; DRUG INTERACTION; DRUG QUALITY; DRUG SAFETY; EMBASE; HEALTH CARE PERSONNEL; HUMAN; MEDICAL SPECIALIST; MEDICATION ERROR; MEDLINE; ONCOLOGY; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; PRESCRIPTION; REVIEW; TOXICITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; DRUG MONITORING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERDISCIPLINARY COMMUNICATION; MEDICATION ERRORS; NEOPLASMS; ONCOLOGY SERVICE, HOSPITAL; PHARMACEUTICAL SERVICES; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; TREATMENT REFUSAL;

EID: 39749147038     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9157-4     Document Type: Review

References (54)

1. Knox RA. Doctor's orders killed cancer patient. Boston Globe 1995;23:1 Metro/Region.
2. Liekweg A, Westfeld M, Jaehde U. From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer care. Support Care Cancer 2004;12:73-9.
3. Bremberg ER, Hising C, Nylen U, Ehrsson H, Eksborg S. An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital. J Oncol Pharm Pract 2006;12:75-81.
4. Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 2004;12:626-33.
5. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
6. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155-63.
7. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005;6:93-102.
8. Dranitsaris G, Leung P, Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 2001;9:611-8.
9. Rough SS, Carro GW. Developing and implementing oral 5-HT3 receptor antagonist guidelines: a multidisciplinary process. Pharm Pract Manag Q 1998;18:48-58.
10. Berard CM, Mahoney CD. Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Am J Health Syst Pharm 1995;52:1879-85.
11. Engstrom C, Hernandez I, Haywood J, Lilenbaum R. The efficacy and cost effectiveness of new antiemetic guidelines. Oncol Nurs Forum 1999;26:1453-8.
12. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thoson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The cochrane effective practice and organization of care review group. BMJ 1998;317:465-8.
13. Dranitsaris G, Warr D, Puodziunas A. A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer 1995;3:183-9.
14. Sano HS, Waddell JA, Soimando DA, Doulaveris P, Myhand R. Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. J Oncol Pharm Pract 2005;11:21-30.
15. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004;5:489-96.
16. Larn MSH, Ignoffo RF. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Pract 2003;9:45-85.
17. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998;45:539-44.
18. Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2005;55:117-42.
19. Joerger M, Schellens JH, Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods Find Exp Clin Pharmacol 2004;26:531-45.
20. Garabedian-Ruffalo SM, Syrja-Farber M, Lanius PM, Plucinski A. Monitoring of drug-drug and drug-food interactions. Am J Hosp Pharm 1988;45:1530-34.
21. American Society of Consultant Pharmacists. Guidelines on preventing medication errors in pharmacies and long-term care facilities through reporting and evaluation. http://www.ascp.com/advocacy/briefing/patientsafety.cfm (accessed 06 March 2007).
22. Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington, DC: National Academy Press; 2000.
23. Thomas EJ, Studdert DM, Burstin HR, Orav EJ, Zeena T, Williams EJ, et al. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care 2000;38:261-71.
24. Phillips J, Beam S, Brinker A, Holquist C, Honig P, Lee LY, et al. Retrospective analysis of mortalities associated with medication errors. Am J Health Syst Pharm 2001;58:1835-41.
25. Slama C, Jerome J, Jacquot C, Bonan B. Prescription errors with cytotoxic drugs and the inadequacy of existing classifications. Pharm World Sci 2005;27:339-43.
26. Mekhjian HS, Kumar RR, Kuehn L, Bentley TD, Teater P, Thomas A, et al. Immediate benefits realized following implementation of physician order entry at an academic medical center. J Am Med Inform Assoc 2002;9:529-39.
27. Harshberger CA, Brockstein B, Carro G, Jiang W, Spath W, Lawton J. Evaluation of outcomes before and after electronic medical record (EMR) and computerized physician order entry (CPOE) system implementation in an outpatient oncology setting [ASCO Annual Meeting Proceedings]. J Clin Oncol 2007;25(18S):17058.
28. Greenberg A, Kramer S, Welch V, O'Sullivan E, Hall S. Cancer Care Ontario's computerized physician order entry system: a province-wide patient safety innovation. Healthc Q 2006;9(Spec Issue):108-13.
29. Koppel R, Metlay JP, Cohen A, Abaluck B, Localio AR, Kimmel SE, et al. Role of computerized physician order entry systems in facilitating medication errors. JAMA 2005;293:1197-1203.
30. Limat S, Drouhin JP, Demesmay K, Tissot E, Jacquet M, Woronoff-Lemsi MC. Incidence and risk factors of preparation errors in a centralized cytotoxic preparation unit. Pharm World Sci 2001;23:102-6.
31. Fabia AS, Rodrigo EC, Mari AA, Cubells DA, Torres NVJ. Pharmaceutical validation as a process of improving the quality of antineoplastic treatment. J Oncol Pharm Pract 2005;11:45-50.
32. Goldspiel BR, DeChristoforo R, Daniels CE. A continuous-improvement approach for reducing the number of chemotherapy-related medication errors. Am J Health Syst Pharm 2000;57(Suppl 4):S4-S9.
33. Mader I, Fürst-Weger PR, Mader RM, Semenitz EI, Terkola R, Wassertheurer SM. Extravasation of cytotoxic agents: compendium for prevention and management. Heidelberg: Springer; 2003.
34. Womer RB, Tracy E, Soo-Hoo W, Bickert B, DiTaranto S, Barnsteiner JH. Multidisciplinary systems approach to chemotherapy safety: rebuilding processes and holding the gains. J Clin Oncol 2002;20:4705-12.
35. France DJ, Miles P, Cartwright J, Patel N, Ford C, Edens C, et al. A chemotherapy incident reporting and improvement system. Jt Comm J Qual Saf 2003;29:171-80.
36. Mueller T. Typical medication errors in oncology: analysis and prevention strategies. Onkologie 2003;26:539-44.
37. WHO. Adherence to long-term therapies-evidence for action. Geneva: World Health Organization; 2003.
38. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
39. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652-61.
40. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993;11:1189-97.
41. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother 2005;39:319-28.
42. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998;36:1138-61.
43. Haynes R, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005;CD000011.
44. Levine AM, Richardson JL, Marks G, Chan K, Graham J, Selser JN, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987;5:1469-76.
45. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. Cancer 1990;65:17-22.
46. Barron TI, Connolly RM, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen. Cancer 2007;109:832-839.
47. Simons S, Roth S, Arjukese A, Braun M, Ko Y, Kuhn W, et al. Measuring compliance in patients receiving oral capecitabine. Onkologie 2006;29(Suppl.3):205.
48. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
49. Van Mil JW, Schulz M, Tromp TF. Pharmaceutical care, European developments in concepts, implementation, teaching, and research: a review. Pharm World Sci 2004;26:303-11.
50. ASHP guidelines on a standardized method for pharmaceutical care. American Society of Health-System Pharmacists. Am J Health Syst Pharm 1996;53:1713-6.
51. Hoare D, Beer C. Guidelines for the pharmaceutical care of cancer patients. Pharm J 1995;255:841-2.
52. Working Party Report. Pharmaceutical care of cancer patients in the community. Pharm J 1997;258:54-8.
53. Broadfield L. Pharmaceutical care in oncology pharmacy practice: A method for using outcome indicators. J Oncol Pharm Pract 1995;1:9-14.
54. Macintyre J, Dalrymple H, MacLean F, Lannigan N, Hudson SA. Development of a system for reporting pharmaceutical care issues in cancer patients receiving chemotherapy. Pharm J 2003;271:266-7.